December 31, 2024 (Globalinvestorideas.com Newswire) Globalinvestorideas.com, a go-to platform for big investing ideas for stock traders, including biotech and medical tech stocks reports on trading and news for Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.
Aethlon is trading up today on investor speculation of bird flu stocks, currently trading at $0.7500, up 0.0893, gaining 13.6107% on volume of over 2.6 Million shares as of this report.
According to Sciencealert.com today, “The ongoing spread of bird flu in the United States has alarmed experts – not just because of human cases causing severe illness, but also due to troubling new instances of infections in cats.”
“A sample of the virus found in a critically ill patient in the United States has shown signs of mutating to better suit human airways, although there is no indication it has spread beyond that individual, authorities report.”
“Earlier this month, officials announced that an elderly Louisiana patient was in “critical condition” with a severe H5N1 infection.”
On December 20th, Aethlon Medical, Inc. (NASDAQ: AEMD) provided a statement of its investigational medical device with respect to H5N1 avian influenza “Bird Flu.”
Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in Louisiana, and yesterday’s declaration of a state of emergency in California.
Paid news dissemination for Aethlon Medical.
The Aethlon Hemopurifier is an investigational extracorporeal medical device designed to remove enveloped viruses and extracellular vesicles from the bloodstream. The device incorporates plasma separation, size exclusion, and affinity binding to a proprietary resin containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical grade diatomaceous earth. Enveloped viruses and extracellular vesicles contain the sugar mannose on their surface, which is the therapeutic target of the GNA.
Aethlon has previously contracted Battelle labs to examine the in vitro removal of influenza viruses including H5N1 by a scaled down version of the Aethlon Hemopurifier. In this experiment, cell culture media was spiked with the H5N1 virus and continuously circulated over the device. Samples were taken periodically to examine viral removal by the device. In this study, a miniature version of the device removed 99% of H5N1 following 6 hours of treatment.
While the Aethlon Hemopurifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier has a “breakthrough device” designation with the FDA for life-threatening viruses for which there is no effective treatment.
Recent news release
https://www.investorideas.com/news/2024/12201AEMD-Hemopurifier-H5N1-Bird-Flu.asp
Biotech stocks to watch:
Research more Biotech and medical technology stocks with Investorideas.com free stock directory
Disclaimer
Global Investor Ideas is part of the Investorideas.com content umbrella and is owned by Econ Corporate Services Inc. For Investorideas disclosure and disclaimer please visit the site directly
Disclaimer/Disclosure: GlobalInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by GlobalInvestorideas and investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. If we are not the source for content but just a publisher , please contact the source of all content for questions and info. We are not responsible for third party content.